Priveterra Acquisition Corp. II, operating as AEON Biopharma, Inc., disclosed an updated corporate presentation on October 23, 2026, regarding the development of ABP-450 as a potential clinically substitutable therapeutic alternative to BOTOX. During Q3 2026, the company received